HER2

Pharma

Boehringer's Hernexeos earns FDA's 2nd national priority nod

The drug can now be used as an initial treatment option for certain lung cancer patients with a speedy label expansion five months after its market debut.

Zoey Becker Feb 26, 2026 3:22pm

Jazz touts Ziihera as HER2 agent of choice in stomach cancer

Jan 6, 2026 3:25pm

FDA approves AZ/Daiichi's Enhertu in 1st-line breast cancer

Dec 15, 2025 4:15pm

Pfizer details Tukysa's 1st-line data in HER2 breast cancer

Dec 10, 2025 8:15am

FDA signs off on Bayer's HER2-mutated lung cancer med Hyrnuo

Nov 19, 2025 4:52pm

Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod

Nov 14, 2025 10:52am